REGAIN CONTROL OVER ADDICTION

Introducing the first prescription digital therapy designed to treat Substance Use Disorder

reSET®: FOR SUBSTANCE USE DISORDER

Pear Therapeutics has developed reSET®, a mobile medical application, to be used in conjunction with outpatient therapy for treating Substance Use Disorder (SUD)

Patient-Facing Smartphone Application

Clinician-Facing Web Interface

reSET® AS A TREATMENT TOOL FOR SUBSTANCE USE DISORDER

reSET®demonstrates improved abstinence and treatment retention when used in conjunction with face-to-face therapy to treat SUD related to stimulants, marijuana, cocaine and alcohol

 

  • 507 patients with SUD across 10 treatment centers nation-wide were randomized to receive either face-to-face therapy, or a reduced amount of face-to-face therapy plus reSET®.
  • Patients received 12 weeks of typical outpatient treatment with or without reSET® (reSET® was substituted for a portion of face-to-face therapy).

 

ABSTINENCE

  • Abstinence was measured twice weekly via urine analysis, breathalyzer, and self-reports.
  • In patients who were dependent on stimulants, marijuana, cocaine, or alcohol (n=395), 58.1% of patients receiving reSET® were abstinent in study weeks 9-12, while 29.8% of patients receiving face-to-face therapy alone were abstinent during the same time frame (p<0.01).
  • Participants who tested positive for drug use at the start of the study (n=191), 26.7% of patients receiving reSET® were abstinent in study weeks 9-12, while 3.2% of patients receiving traditional face-to-face therapy were abstinent during the same time frame (p<0.01).
All Patients
graph-1-2
Patients Non-Abstinent at Baseline
graph-2-23

RETENTION

  • Treatment retention is a positive predictor of future, positive outcomes such as decrease in drug use2-4.
  • Patients receiving reSET® showed statistically significant improvement in retention compared to face-to-face therapy alone (p=0.0316). At the end of 12 weeks of treatment 59% of patients receiving face-to-face therapy were retained in the study compared to 67% of patients receiving reSET®.

graph-3-1

table-for-graph-3-2

 

ENGAGEMENT

  • User Engagement was measured in the pivotal study by comparing the average number of reSET® modules completed each week between patients abstinent and non-abstinent throughout the 12-week study.
  • Results show how all patients remain engaged throughout the study, and interestingly, the patients that were abstinent completed more modules per week.
Modules Completed per Week
Time Spent on Modules

 

1. Campbell et al. Am J Psychiatry. 2014.
2. Hubbard et al. Psychol Addict Behav. 1997.
3. Simpson. Am J Psychiatry. 1979.
4. Zhang et al. Addiction. 2003.
ClinicalTrials.gov Identifier: NCT01104805

For more information, please contact us

Contact Us

*reSET® is not yet available for sale in the United States